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See Article, pages 847–854Aging is characterized, amongst other ailments, by an increased
prevalence of symptoms of the metabolic syndrome such as ele-
vated blood pressure, dyslipidemia and insulin resistance, which
rise from 7% in the 20–29 year-old population to 44% in the 60–
69 year-old population [1]. Excessive accumulation of fat in the
liver, or steatosis, is a predictor of these metabolic alterations
and is as such often considered as the hepatic manifestation of
the metabolic syndrome. Ectopic fat accumulation as well as
inappropriate lipid partitioning in the liver is believed to play a
driving role in the etiology of insulin resistance [2] and consid-
ered by many as the primary step in the development of non-
alcoholic fatty liver disease (NAFLD). During the progression of
NAFLD, simple steatosis evolves, in predisposed individuals,
towards a condition termed non-alcoholic steatohepatitis
(NASH), diagnosed as a combination of steatosis, inﬂammation
and hepatocyte ballooning. Liver injury may worsen and progress
to ﬁbrosis and cirrhosis and eventually to hepatocellular carci-
noma [3], conditions of unmet therapeutical need as liver trans-
plantation is still the only curative option [4]. Multiple factors
have been incriminated in the progression of NAFLD, such as
excessive consumption of simple carbohydrates leading to
enhanced hepatic lipogenesis, altered composition of the gut
microbiome and aberrant immune-inﬂammatory responses, all
of which interact with genetic factors [5]. Furthermore, NAFLD
is a recognized independent risk factor for cardiovascular disease
and type 2 diabetes mellitus [6].
From a molecular perspective, several mechanisms have been
proposed to explain the progression of NAFLD, the most common
being the two-hit hypothesis [7]. Whereas the second hit
includes a variety of factors, such as hepatocyte senescence, oxi-
dative stress, increased lipid peroxidation products, gut ﬂora bio-
products, or mitochondrial dysfunction resulting from a lipotoxic
environment, the ﬁrst hit is often considered to be a lipotoxic
insult. Many of these alterations are accelerated by aging. Proper
lipid homeostasis in the liver relies in large part on the physiolog-
ical dynamics of subcellular lipid partitioning, lipid assembly and
lipolysis of lipid droplets and lipid degradation via mitochondrialJournal of Hepatology 20
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Open access under CC BY-NC-ND license.oxidation and lipid ﬂuxes to the autophagic system. The
proteasomal, lysosomal and autophagosome pathways are
age-regulated pathways implicated in the control of lipid
accumulation in the liver [8–10]. Interestingly, the global
age-related changes in liver chromatin structure [11] hint at
alterations in epigenomic events, which are controlled by
transcription factors and associated co-activating or
co-repressing proteins. Accordingly, co-repressor-associated
de-acetylases, such as Sirt1 and HDAC1, as well as the histone
acetyl transferase p300 [12–14], all of which are involved in lipid
homeostasis, display altered expression proﬁles in the aging liver.
Furthermore, the expression levels of several nuclear receptors,
many of which are involved in the control of metabolic adapta-
tion to environmental stimuli, are affected in the liver of
senescence-prone mice [15,16]. Amongst such nuclear receptors
is the nuclear bile acid receptor FXR.
FXR (NR1H4) regulates liver function by negatively interfering
with bile acid synthesis through the SHP-LRH1 axis, with glycol-
ysis through direct inhibition of ChREBP [17] and with lipogene-
sis through the SHP-SREBP1c axis [18]. Together with the
induction of PPARa expression, activation of hepatic FXR thus
leads to reduced hepatic fatty acid and triglyceride synthesis
and increased fatty acid oxidation. In line, FXR-deﬁcient mice
display a moderate steatosis. Xiong and collaborators report in
this issue of the Journal of Hepatology a novel mechanism
resulting in the decrease of FXR protein expression in the liver
of aging C57BL/6 mice and show this favors age-induced
steatosis. They further show that aging promotes endoplasmic
reticulum (ER) stress, which can be alleviated by the treatment
of aged mice with the chemical chaperones tauro-ursodeoxychol-
ic acid (TUDCA), a hydrophilic bile acid derivative, or 4-phenylbu-
tyrate (PBA), a compound chemically unrelated to TUDCA, and
resulted in an increased expression of FXR. By contrast, adminis-
tration of the ER stress-inducer tunicamycin led to a marked
down-regulation of FXR. Using a combination of molecular
approaches and JNK1-deﬁcient mice, the authors showed that
the down-regulation of FXR is the result of JNK1-mediated
inhibition of HNF1a transcriptional activity. Since HNF1a is a
known regulator of FXR gene transcription, the authors conclude
that activation of the ER stress-JNK1-HNF1a signaling cascade is
responsible for the down-regulation of FXR. This mechanism
reinforces the idea of pharmacological activation of FXR as a
possible therapeutic intervention in NAFLD patients, a hypothesis14 vol. 60 j 689–690
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currently tested in a phase IIb trial with the bile acid derivative
INT747, a potent FXR activator [19]. The aging liver is also char-
acterized by a signiﬁcant loss in the regeneration capacity of
hepatocytes as shown by a marked decrease in telomere length.
Interestingly, FXR positively controls hepatic regeneration by
directly stimulating Foxm1b expression [20], thus strengthening
the potential role of FXR as a therapeutic target in liver diseases.
The results presented by Xiong et al. further add to our under-
standing on the mechanisms of age-related progression of
chronic liver diseases related to steatosis. However, inﬂamma-
tion, hepatocyte ballooning and especially ﬁbrosis are major
characteristics in the progression of NAFLD to a pathological con-
dition. Whether activation of FXR directly acts on these two
parameters is not yet fully understood, but deserves further
investigation to fully appreciate the spectrum of the biological
actions and potential pharmacological applications of FXR.Conﬂict of interest
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